Risultati per: Raccomandazioni Melanoma per pazienti e cittadini

In 80 centri italiani. ‘Non si parla più solo di sopravvivenza’

Nel 2023 sono stati 4,5 milioni, pari al 7,6% della popolazione, erano il 7% nel 2022. I motivi: problemi economici, liste d’attesa e difficoltà di accesso

Schillaci, ‘Dichiara il tuo Sì in comune. Donare è una scelta di vita’. Al via campagna negli Uffici anagrafe

Giornata nazionale donazione organi,’Dichiara tuo Sì in comune’

50% utenti chiede ai siti più notizie su malattie e prevenzione

50% utenti chiede ai siti più notizie su malattie e prevenzione

This cohort study assesses the incidence rate of second primary invasive melanoma at least 30 days after the first based on data from deidentified records of all invasive melanomas diagnosed in 2008 to 2020, obtained from the Cancer Registry of Norway.

This Viewpoint reviews the evidence for immune checkpoint inhibitor use in the adjuvant setting, discusses the individual and societal risks, benefits, and costs associated with immune checkpoint inhibitors, and highlights the need for more targeted patient selection approaches.

In Reply I thank Pang and Sun for their comments on our meta-analysis. First, a statement on the key findings: with CheckMate 714 included (see Comment published along with article), the pooled overall survival (OS) and progression-free survival (PFS) hazard ratios (HRs) for nivolumab plus ipilimumab vs nivolumab alone were 0.98 (95% CI, 0.88-1.08) and 0.91 (95% CI, 0.83-1.00), respectively, with 5 of 9 studies having a numerically lower median OS. The combination was associated with substantially higher treatment-related discontinuations and high-grade adverse events. These numbers very strongly support the stated conclusions.

This retrospective cross-sectional study illustrates national-level trends in immunohistochemistry staining for the diagnosis of melanoma in older adult patients enrolled in Medicare.

To the Editor Serritella and Shenoy conducted an interesting meta-analysis to assess the relative efficacy of nivolumab plus ipilimumab vs nivolumab for the treatment of advanced cancers other than melanoma. Based on 8 studies with 1727 patients (854 in the nivolumab plus ipilimumab group vs 873 in the nivolumab group), the authors concluded that patients in the combination therapy group did not show clinically meaningful overall survival or progression-free survival benefits compared to those in the monotherapy group. Furthermore, treatment-related higher-grade toxicity and discontinuation rates were substantially higher with the combination therapy. However, several methodological issues need to be clarified.

‘Spesso sono forme lievi non diagnosticate in età infantile’

Progetto Pascnet contro la nuova emergenza di sanità pubblica

Il cittadino deve scegliere liberamente medico e luogo cure

Frasi e immagini per sensibilizzare sui percorsi di cura

This case series identifies patient-level and tumor-level characteristics of melanoma in 48 Black patients at 2 tertiary care centers.